• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Biotie Therapies

edit

Biotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

Milestones

edit

• 
  Biotie Therapies added Thomas Taapken as CFO.
  Posted 1/12/11 at 8:13pm
• 
  Biotie Therapies added Timo Veromaa as President and CEO.
  Posted 1/12/11 at 8:13pm
• 
  Biotie Therapies acquired Synosia Therapeutics for $122M. (1/11/11)
  Posted 1/12/11 at 8:17pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. Biotie buys CNS developer Synosia in $121.5M deal Read more: Biotie buys CNS developer Synosia in $121.5M deal - FierceBiotech http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss&utm_source=rss#ixzz1A (fiercebiotech.com) [edit]